Related Experiment Video
Updated: Jun 13, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Botulinum neurotoxin type-A for primary stabbing headache: an open study
Elcio Juliato Piovesan1, Helio Ghizoni Teive, Pedro André Kowacs
1Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba, PR, Brazil. piovesan@avalon.sul.com.br
Arquivos De Neuro-Psiquiatria
|May 14, 2010
Summary
Botulinum neurotoxin type-A (BoNTA) effectively treated primary stabbing headache in most patients. This therapy provided sustained relief for many, offering a promising new option for this debilitating condition.
Area of Science:
- Neurology
- Headache Medicine
Background:
- Primary stabbing headache is a brief, severe headache type.
- It is more common in women and often resistant to standard treatments.
Purpose of the Study:
- To evaluate the efficacy of botulinum neurotoxin type-A (BoNTA) for primary stabbing headache.
Main Methods:
- A study involving 24 patients with primary stabbing headache.
- Treatment administered was botulinum neurotoxin type-A (BoNTA).
Main Results:
- Three patients (12.5%) achieved complete remission.
- Nineteen patients (79.2%) experienced a reduction in headache frequency and intensity.
- Symptomatic improvement began within two weeks and lasted approximately 63 days.
- Two patients (8.3%) did not respond to BoNTA therapy.
Conclusions:
- Botulinum neurotoxin type-A (BoNTA) demonstrates significant therapeutic potential for primary stabbing headache.
- BoNTA offers a viable and effective treatment option for patients with this condition.
